mardi 17 octobre 2017

Onco Actu du 17 octobre 2017

1. Biologie

Cancers Relapse by Feeding Off Immune Signals [The Scientist]

4.2 Dép., diag. & prono. - Génome

From UCSF, New Sequencer Reveals Cancer Blueprints, Cell By Cell [Xconomy]

5.12 Immunothérapies

2017 Immuno-Oncology Medicines in Development [Phrma]

After 5 years and 2 clinical trials, Patient #1 stops cancer treatment [The Inquirer]

5.12.5 Immunothérapies - Pharma

U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review [BMS]

5.12.8 Immunothérapies - Economie

New gene therapy treatment could hit $1M per patient because of additional costs [USA Today]

5.13 WCLC

Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032 [BMS]

Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer [Pfizer]

Pfizer’s son of Xalkori impresses in phase 2 NSCLC trial [Xconomy]

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer [Takeda]

Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis [Lilly]

World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions [IASLC]

Efficacy of Nivolumab is Enhanced in Small Cell Lung Cancer Patients with High Tumor Mutation Burden with or without Ipilimumab [IASLC]

After getting skunked by rivals, Pfizer touts ‘breakthrough’ cancer drug lorlatinib, heads to the FDA [EndPoints]

Chi-Med, AstraZeneca lung cancer drug shrinks resistant tumors [Reuters]

5.2 Pharma

Exelixis’ Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma [Exelixis]

Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma [Exelixis]

US FDA accepts supplemental Biologics License Application for Imfinzi in locally advanced unresectable non-small cell lung cancer [AstraZeneca]

Exelixis drug improves overall survival in liver cancer patients [Reuters]

5.3 Traitements - FDA, EMA, NICE...

EMA’s Business Continuity Plan for Brexit published [EMA]

Are new cancer treatments improving survival or quality of life? [Healthcare Economist]

EMA counters the academics who criticized the cancer drug approval process [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

EMA Recommends Extension of Indications for Abiraterone Acetate [ESMO]

Copanlisib Approved for Follicular Lymphoma [NCI]

5.4 Traitements - Economie

The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad [Forbes]

6. Lutte contre les cancers

Bridge Project Q&A: “Big Idea” Winners on Bridging the River in Boston Cancer Research [Xconomy]

6.1 Observation

7 Million American Men Carry Cancer-Causing HPV Virus [NY Times]

More men than women infected with oral human papillomavirus [Reuters]

6.10.1 Politiques (USA)

When it comes to pharma donations, Trump was with the elephant in the room [STAT]

6.7 DMP, Big Data & applis

Apple explored buying a medical-clinic start-up as part of a bigger push into health care [CNBC]

6.9 Controverses

Incyte's claims that Bristol Myers-Squibb IDO medication was stolen by ex-staffer set for trial hearing [FierceBiotech]

Incyte and Flexus: The Grappling Continues [In the Pipeline]